Incyte

(NASDAQ:INCY)

$78.76

0.50[0.64%]

Last update: 12:30PM (Delayed 15-Minutes)
Get Real Time Here

Day Range78.22 - 79	52 Wk Range65.07 - 84.86	Open / Close78.3 / -	Float / Outstanding183.6M / 222.5M
Vol / Avg.159.4K / 1.4M	Mkt Cap17.5B	P/E19.86	50d Avg. Price72.18
Div / Yield-	Payout Ratio-	Total Float183.6M	EPS0.51

Incyte Stock (NASDAQ:INCY), Quotes and News Summary

Q: What sector and industry does Incyte (INCY) operate in?

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Incyte Stock (NASDAQ: INCY) stock price, news, charts, stock research, profile.

Day Range78.22 - 79	52 Wk Range65.07 - 84.86	Open / Close78.3 / -	Float / Outstanding183.6M / 222.5M
Vol / Avg.159.4K / 1.4M	Mkt Cap17.5B	P/E19.86	50d Avg. Price72.18
Div / Yield-	Payout Ratio-	Total Float183.6M	EPS0.51

Sector: Health Care.Industry: Biotechnology

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Earnings

Q4 2022		Est.		Actual		Surprise
EPS		(EXPECTED)2023-02-07
REV		(EXPECTED)2023-02-07

Q3 2022		Est.		Actual		Surprise
EPS		0.740		0.600		-0.1400
REV		848.190M		823.303M		-24.887M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

How do I buy Incyte (INCY) stock?

You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.

View our list of the best stock brokerages.

Who are Incyte's (INCY) competitors?

Other companies in Incyte’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).

What is the target price for Incyte (INCY) stock?

The latest price target for Incyte (NASDAQ: INCY) was reported by RBC Capital on Wednesday, November 2, 2022. The analyst firm set a price target for 82.00 expecting INCY to rise to within 12 months (a possible 4.11% upside). 16 analyst firms have reported ratings in the last year.

Current Stock Price for Incyte (INCY)?

The stock price for Incyte (NASDAQ: INCY) is $78.76 last updated Today at November 28, 2022, 5:30 PM UTC.

Does Incyte (INCY) pay a dividend?

There are no upcoming dividends for Incyte.

When is Incyte (NASDAQ:INCY) reporting earnings?

Incyte’s Q4 earnings are confirmed for Tuesday, February 7, 2023.

Is Incyte (INCY) going to split?

There is no upcoming split for Incyte.

What sector and industry does Incyte (INCY) operate in?

Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

SPY

QQQ

BTC/USD

DIA

GLD

TLT

SPY

QQQ